Abstract:Infections with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis account for 25 million patients worldwide. Tuberculosis is the most common opportunistic infectious disease in HIV-infected subjects, and HIV infection is a high-risk factor for tuberculosis. The convergence of HIV and tuberculosis is a disaster practically unequalled in medical history.1 This is a rare case report on the topic of pulmonary miliary tuberculosis and intestinal tuberculosis with AIDS. A 38-year-old man was admitted on October 5, 2007 with a 2-month history of intermittent abdominal pain, and had been treated with spasmolytic drugs without effect. A colonoscopy showed an annular bulging with about 1.0 × 1.6 cm ulcers 40 cm from the anus. The colonic lumen was narrowed and the histopathology indicated chronic inflammation with necrosis and granulation tissue. He had several sex partners, was found to have syphilis in May 2006, and had been treated for 15 days only. On 12 September 2007 he was known to have an HIV infection and had been treated with antiviral drugs. On admission to hospital his vital signs were: temperature 37.6 °C, pulse 86/min, respiration 18/min, blood pressure 110/60 mmHg (1 mmHg = 0.133 kPa), he was mentally lucid, his lymph nodes were not enlarged but there was decreased breath sound over both lungs. His heart was normal and abdomen soft but with tenderness over the left lower quadrant, his liver and spleen were not palpate. His muscle strength and tendon reflexes were all normal. The laboratory tests results were hemoglobin 110 g/L, platelet (PLT) 77.30 × 109/L, red blood cell count 3.70 × 1012/L, white blood cell count 5.33 × 109/L, C-reactive protein 87.00 mg/L, immunoglobulin (Ig) A 1.97 g/L, IgG 30.30 g/L, serum albumin 32.3 g/L, alanine aminotransferase 60 U/L, aspartate aminotransferase 67 U/L, blood urea nitrogen 4.51 mmol/L, creatinine 49.7 × mol/L, cell-mediated immunity CD4+ cell count 85 × 106/L, CD8+ cell count 591 × 106/L. On B-ultrasound examination hepatomegaly, splenomegaly and celiac lymphadenectasis were present. A chest computed tomography (CT) showed bilateral pulmonary miliary tuberculosis. An abdominal CT showed lymphadenectasis at the porta hepatis. A colonoscopy displayed an ulcerative proliferative mass at the splenic flexure. Adjacent to the mass involving the intestinal wall was a 1.0 × 1.6 cm ulcer (Fig. 1). The biopsy showed chronic inflammation with atypical hyperplasia. Based on the clinical, laboratory and histopathologic findings a diagnosis of AIDS with pulmonary military tuberculosis and intestinal tuberculosis was made. Highly active antiretroviral therapy (HAART) with isoniazid, rifampicin, pyrazinamide and ethambutol was given. One month afterwards the patient's general condition improved, his fever subsided, part of pulmonary lesion was absorbed and his CD4+ cell count increased up to 165 × 106/L, but his abdominal pain became aggravated. A second colonoscopy showed the colonic lumen much narrowed and a left hemi-colon resection was performed. Typical tuberculous granuloma with caseous necrosis was shown in the histopathology (see 2, 3), and a tissue culture showed the presence of tuberculosis. HAART therapy and anti-tuberculosis treatment continued and subsequently all symptoms improved after the combination of HAART with anti-tuberculosis treatment. Thereafter the patient's symptoms gradually disappeared and 1 month later the patient was discharged without abdominal pain or other symptoms. First colonoscopy shows an ulcerative proliferative mass 40 cm from the anus. Tuberculous granuloma shown in the excised colon. Caseous necrosis in the excised specimen. Active tuberculosis can be triggered by a patient's weakened immune function and has become the second most common killer of patients with HIV/AIDS worldwide. The incidence of tuberculosis can be very high in Africa (356/100 000 population) and mortality is 81/100 000, but is lower in the USA (incidence: 41/100 000, mortality: 5.9/100 000).2 HIV is the highest single risk factor for boosting tuberculosis in adults, and tuberculosis can occur early in the course of HIV infection. The clinical presentation of tuberculosis can be modified by immune suppression, which has a real influence on the prognosis of HIV infection.3 AIDS patients with secondary intestinal tuberculosis are rarely reported. Most (80%) of the intestinal tuberculous lesions are in the ileocecum, the remainder lie in the ileum or colon, which are mostly secondary to pulmonary tuberculosis, and cause narrowing or obstruction in the advanced stage. Some of these can even result in an adhesive ileus because of the complication of tuberculous peritonitis.4 The reason why it was easy to misdiagnose intestinal tuberculosis in our patient was that both clinical and endoscopic features were atypical. The abdominal pain became aggravated but the patient's general symptoms improved after the combined treatment of HAART and anti-tuberculosis therapy. Intestinal tuberculosis mimics many other conditions such as Crohn's disease, malignancy and infectious diarrhea, and is often difficult to diagnose. Only when the biopsy found caseous necrosis or acid fast bacilli at microscopy, we were able to establish a precise diagnosis. The increased prevalence of extra-pulmonary tuberculosis in HIV patients presents a special diagnostic challenge. The major factor hampering our ability to diagnose tuberculosis in HIV patients was the lack of a sensitive, specific and rapid diagnostic test. The WHO directly observed therapy short course program relies on the microscopic identification of M. tuberculosis. However, due to the alteration of the normal host immune response to M. tuberculosis in HIV patients, cavitation and the transfer of M. tuberculosis into the respiratory secretions are markedly reduced. Indeed, smear-negative tuberculosis has been linked to a poor treatment outcome. The increased prevalence of extra-pulmonary forms of tuberculosis in HIV-infected patients is a further challenge to the management of tuberculosis in resource-poor settings where access to histopathology and advanced imaging tests are limited or absent. The lack of a reliable, rapid test for smear-negative tuberculosis not only means that we often miss a correct diagnosis but also that patients are often erroneously started on anti-tuberculosis therapy on the basis of a clinical presentation alone.5 The WHO has updated the guidelines for the management of smear-negative and extra-pulmonary tuberculosis and it has provided algorithms for the management of smear-negative pulmonary and extra-pulmonary tuberculosis in HIV-prevalent communities. The organization highlights the need for HIV testing of all tuberculosis suspects, rather than only confirmed tuberculosis cases. Furthermore, the diagnostic algorithms used for the management of extra-pulmonary tuberculosis are much clearer. They provide more detailed advice on which tests to employ and improve the definitions of common extra-pulmonary forms of the disease to aid clinicians.6 Patients co-infected with HIV and M. tuberculosis have a greatly increased risk of developing active tuberculosis.5 In the course of anti-tuberculosis therapy the abdominal pain of our patient became aggravated. The possible reason may be the emergence of complications, the existence of drug-resistant tuberculosis,7 or HAART treatment-related immune reconstitution inflammatory syndrome (IRIS). During the course of treatment the CD4+ cell count increased from 85 × 106/L up to 165 × 106/L. This hints that IRIS is the most likely cause. As we know, potent antiretroviral therapy can substantially reduce both the likelihood of opportunistic infections and the progression of HIV infection to AIDS. Shortly after starting HAART as many as 25% of patients experience clinical worsening because of subclinical opportunistic pathogens or a recurrence of a previously disease. One study has indicated that the initiation of HAART therapy at 4–12 weeks of tuberculosis treatment in advanced AIDS patients may be safe and effective.8 In this case, one month after the patient was treated with HAART and the anti-tuberculosis treatment, his CD4+ cell count increased and his symptoms improved, but the local intestinal lesion was aggravated, which is commonly seen in IRIS. AIDS with locally aggravated intestinal tuberculosis is rare, and should be given more attention.

Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection

Pulmonary Miliary Tuberculosis and Intestinal Tuberculosis Co‐infected with AIDS

Clinical impact of plasma concentrations of first-line antituberculosis drugs

Impact of Antiretroviral Therapy on Anemia, Hepatotoxicity, and Immune Reconstitution Inflammatory Syndrome in HIV-Tuberculosis Co-Infected Patients

Effects of Rifampicin, CYP2B6 and ABCB1 Polymorphisms on Efavirenz Plasma Concentration in Chinese Patients Living with HIV and Tuberculosis.

Partial adhesive small bowel obstruction due to peritoneal tuberculosis HIV/AIDS patient: A case report

The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis

Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial

Clofazimine pharmacokinetics in HIV‐infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics

Drug-induced liver injury in HIV-infected patients with active tuberculosis

Clinical Analysis of Antituberculosis Drug-Induced Hepatotoxicity in HIV/TB Patients

HIV infection impairs the host response to Mycobacterium tuberculosis infection by altering surfactant protein D function in the human lung alveolar mucosa

Trends in and Risk Factors for Drug Resistance in Mycobacterium tuberculosis in HIV-Infected Patients

Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda

Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis